Clinical Sessions for Recertification (CE)
Educational Sessions (CE)
Planned in cooperation with the American College of Clinical Pharmacy
ACPE Activity #0217-9999-19-164-L01-P
2.00 Contact Hours | Application-based
Katie Cardone, Pharm.D., BCACP, FASN, FCCP, FNKF
Albany College of Pharmacy and Health Sciences
AstraZeneca: Advisory Board (Status: Terminated --- May 2018); Fresenius Medical Care (Spouse/Partner) : Employee (Status: Ongoing); Janssen: Grant Recipient (Status: Ongoing); Wolters Kluwer Kelly: Consultant (Status: Ongoing)
This session is designed to provide an evidence-based update regarding hot topics in Type 1 and Type 2 diabetes. This two-hour session will focus on three primary issues in diabetes: cardiovascular outcomes, renal outcomes, and non-insulin therapy. These case-based presentations will allow the learner to critically evaluate the literature while designing a patient-specific therapeutic plan. The first two presentations within this session will review the evidence for cardiovascular and renal outcomes for glucagon peptide-1 receptor agonist, dipeptidyl peptidase-IV inhibitors, and sodium-glucose cotransporter-2 inhibitors in patients with Type 2 diabetes. The third presentation will focus on the evidence behind non-insulin therapies as a benefit to patients with Type 1 diabetes.
This activity is approved for Board Certified Ambulatory Care Pharmacist (BCACP) recertification credit.